Remdesivir is a drug which was first developed to use against Ebola virus. This virus, on 2014, caused a serious outbreak across the Central Africa. The main victim was specially the villagers. Currently, the world is hoping to treat COVID-19 infected people with this drug. Can Remdesivir fight COVID-19?
According to a report provided by WHO’s R&D Blueprint, the drug, Remdesivir is one of the most hopeful drugs among all the discovered therapeutic ways to treat COVID-19 infected people. This can be said because of the data generated from in-vitro and in-vivo tests. In-vitro test is performed in test tube, while in-vivo test is performed in the living organisms. Based on the data provided by the report, Remdesivir can effectively suppress the development of COVID-19 comparing to other drugs in mice. The report also says that scientists are now planning to perform a clinical trial to figure out the efficacy and safety of Remdesivir. Of course, things will be observed closely in alongside proper care. The report has disclosed that the drug can block the growth of COVID-19 by slowing down the infection process of healthy cells.
The drugs ritonavir and lopinavir, which were used to treat HIV, have also been reviewed by WHO experts. They were used alone and were used along with IFNbeta. The result revealed that among all the repurposed drugs under consideration, these two would be the most appropriate second alternative. Along with Remdesivir, researches are looking forward to run another clinical trial to observe the effects of those two drugs.
Another proposed antiviral medication is Ribavirin, which is used to treat people infected by RSV as well as hepatitis C. However, WHO believes that this one won’t be as effective as Remdesivir.
The draft report also reveals that the experience with the assessment in SARS in Canada during 2003 may have increased the mortality rate than other countries. It also had decreased the concentration of hemoglobin in the body which is a side effect that patients with respiratory problems can not stand with.